NYSE · Asset Management

Tekla Life Sciences Investors (HQL) Stock

$20.15 +1.15% NYSE: HQL Financial Services

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide.

Valuation

MetricValue
Price$20.15
Market Cap$612.72M
P/E Ratio2.99
P/B Ratio1.09
P/S Ratio10.26
EPS (TTM)$6.74
52-Week High$21.32
52-Week Low$12.94
Dividend Yield11.12%

Financials & Margins

MetricValue
ROE36.89%
ROA35.18%
ROCE35.24%
Gross Margin90.69%
Operating Margin331.92%
Net Margin331.92%
Debt/Equity0.00
Current Ratio2.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$45.0M$32.0M$39.0M$87.0M$86.0M
Operating Profit$65.0M$-105.0M$-5.0M$85.0M$86.0M
Net Profit$65.0M$-105.0M$22.0M$85.0M$86.0M
EPS$2.66$-4.07$0.79$3.04$2.96
Op Margin143.3%-328.3%-13.3%98.4%99.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$534.0M$415.0M$403.0M$461.0M$515.0M
Total Liabilities$11.0M$17.0M$1.0M$1.0M$2.0M
Cash$0$0$0$0$0
Borrowings$1.0M$11.0M$0$0$0

Latest News

Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details PR Newswire · Jun 30, 2026 ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS PR Newswire · May 27, 2026 Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts PR Newswire · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$0—$-2.0M
Investing Cash Flow$0$0$0—$25.0M
Financing Cash Flow$0$0$0—$0
Net Cash Flow$0$0$0—$0
Free Cash Flow$0$0$0$0$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA3.09
FCF Yield-0.41%
Quick Ratio2.58
Interest Coverage0.00
Return 1Y66.06%
Return 3Y111.14%
Return 5Y69.07%

Ownership

Insiders Held0.00%
Institutions Held27.64%
Institutions Float Held27.64%
Institutional HolderSharesReport Date
Morgan Stanley1,571,0142026-03-31
Saba Capital Management, L.P.947,3462026-03-31
Penserra Capital Management LLC806,8882026-03-31
Raymond James Financial, Inc.661,3122026-03-31
LPL Financial LLC478,8022026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CCAP $10.86 +0.05% 12.23 $399.96M 11.96%
CION $6.08 +1.59% -19.18 $302.47M 0.00%
ECC $4.04 +0.00% -3.83 $534.12M 0.00%
GAIN $16.59 -1.60% 3.50 $660.65M 9.19%
GIG $5.16 +0.19% 52.73 $172.00M 0.00%

About Tekla Life Sciences Investors

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

Tekla Life Sciences Investors is headquartered in US.

Tekla Life Sciences Investors (HQL) stock trades at $20.15 with a market capitalization of $612.72M. The stock is valued at a price-to-earnings (P/E) ratio of 2.99, price-to-book of 1.09, price-to-sales of 10.26. Over the past 52 weeks the stock has ranged between $12.94 and $21.32, and currently trades 5.5% below its 52-week high. It pays a dividend yielding 11.12%.

On profitability, Tekla Life Sciences Investors generates a return on equity (ROE) of 36.89% — well above the market average, a sign of a high-quality business, return on capital employed of 35.24%, an operating margin of 331.92%, a net profit margin of 331.92%.

Official website: www.abrdnhql.com

Related Financial Services Stocks

BRK.A Insurance - Diversified $733370.00 +0.00% BRK.B FIRE, MARINE & CASUALTY INSURANCE $482.70 +0.00% JPM Banks - Diversified $357.52 +0.34% V Financial - Credit Services $362.50 -2.15% MA Financial - Credit Services $562.95 -2.26% BAC Banks - Diversified $63.17 +0.27% HSBC Banks - Diversified $102.60 -1.06% MS Financial - Capital Markets $203.19 -3.97% GS Financial - Capital Markets $980.75 -5.09% RY Banks - Diversified $206.45 -2.79% WFC Banks - Diversified $83.87 -3.45% MUFG Banks - Diversified $21.94 -2.18%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)Exxon Mobil (XOM)

Screens featuring this stock

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides